Indian Pharmaceutical Supplier to Africa.
Africa is the largest block of our export footprint. M Care supplies WHO-GMP finished dosage forms from Indian manufacturers into eight regulated markets across the continent: Nigeria, Kenya, Ghana, South Africa, Ethiopia, Tanzania, Uganda and Egypt. The Mumbai desk authors CTD and eCTD dossiers for NAFDAC, PPB, FDA Ghana, SAHPRA, EFDA, TMDA, NDA and EDA in parallel, files WHO-PQ and EAC joint assessments where the molecule qualifies, and runs warm-climate cold-chain lanes into Lagos, Mombasa, Durban, Addis Ababa and Accra. We bid into central-stores framework tenders and supply Global Fund, PEPFAR, UNICEF and MSF implementing partners across the continent.
Five-plus authorities, one dossier strategy.
Africa does not register pharmaceuticals from a single desk. A multi-country programme touches at least five national regulators, each with its own CTD variant and timing. NAFDAC (National Agency for Food and Drug Administration and Control, Nigeria) runs review through the NMR e-portal on a six-to-twelve-month window, with physical port-of-entry inspection standard. PPB (Pharmacy and Poisons Board, Kenya) takes six to nine months on WHO-PQ reference products. FDA Ghana lands inside eight to twelve months. SAHPRA (South African Health Products Regulatory Authority) is the strictest at twelve to eighteen months, with an accelerated pathway for priority public-health products.
EFDA (Ethiopian Food and Drug Authority), TMDA (Tanzania Medicines and Medical Devices Authority), NDA (National Drug Authority, Uganda) and EDA (Egyptian Drug Authority) round out the eight authorities most M Care consignments clear. EFDA requires local-agent representation. EDA governs North Africa's largest pharma market and mandates Arabic artwork. The AMA (African Medicines Agency) treaty entered into force on 5 November 2019, the secretariat is being stood up in Kigali, and operational rollout is phased through the late 2020s. The EAC Medicines Regulatory Harmonization programme already runs joint assessments for Kenya, Uganda, Tanzania, Rwanda and Burundi, with a single dossier and mutually recognised registration for ARV, ACT and TB categories.
Procurement in much of Africa flows through state central medical stores rather than open-market purchase orders. KEMSA (Kenya Medical Supplies Authority) and the faith-based MEDS cover most public-sector Kenya demand. NMS (National Medical Stores, Uganda) and JMS (Joint Medical Store, Uganda) split the public and FBO channels. MSD (Medical Stores Department, Tanzania), CMS Ghana and EPSS (Ethiopian Pharmaceuticals Supply Service) anchor their respective markets. Tender cycles run two to three years, with WHO-PQ preferred or mandatory for programmatic buys on ARVs, ACTs and TB fixed-dose combinations. We bid into refresh rounds across the continent on a quarterly cadence.
The Francophone and Anglophone divide matters. UEMOA and ECOWAS WAHO (West African Health Organisation) drive harmonisation across Francophone West Africa, with OCEAC covering the Francophone Central African block. ARV and ACT fast-tracks run under WAHO. Anglophone West Africa routes through ECOWAS WAHO but sits closer to the Anglophone dossier conventions serving NAFDAC and FDA Ghana. AMA is the convergence point for all of these tracks, and dossiers we author today are structured to re-use across AMA, EAC, WAHO and WHO-PQ without a ground-up rebuild.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · info@mcareexports.com · Mon–Sat 09:30–18:30 IST
Six capabilities, pre-assembled.
NAFDAC, PPB, FDA Ghana, SAHPRA dossiers
The Mumbai regulatory team authors CTD and eCTD dossiers for NAFDAC, PPB, FDA Ghana, SAHPRA, EFDA, TMDA, NDA and EDA in parallel. Module 3 is written once per molecule; Module 1 country adaptations, CPPs and legalisation chains are handled in-country through our regulatory correspondents. WHO-PQ and EAC joint-assessment routes are invoked where the product qualifies.
WHO-PQ portfolio
Prequalified ARVs (TLD, TLE, raltegravir, zidovudine-lamivudine, lopinavir-ritonavir, paediatric dispersibles), ACTs (artemether-lumefantrine, artesunate-amodiaquine, artesunate injection), TB FDCs and reproductive-health lines including misoprostol, oxytocin and magnesium sulfate. WHO-PQ status is often the precondition for Global Fund PPM, PEPFAR SCMS and UNICEF Supply Division demand.
Central medical stores tender response
Full technical and commercial pack for KEMSA, NMS Uganda, JMS, MSD Tanzania, CMS Ghana and EPSS Ethiopia. Framework tenders run two to three years with annual refreshes; we track award calendars, pre-position stability and GMP artefacts, and coordinate local-agent filings. Award-to-first-shipment is typically six to ten weeks.
Cold-chain to Lagos, Mombasa, Durban, Addis, Accra
Envirotainer RAP e2 and RKN e1 active containers for 2-8°C biologicals, va-Q-tec passive shippers for 15-25°C ambient, real-time loggers on every pallet. Tarmac dwell at Lagos, Nairobi, Addis and Accra routinely hits 35-45°C; we route through cool-dolly hubs and destination warehousing is generator-backed.
NGO and programme procurement
Named relationships with Global Fund PPM and Wambo.org, UNICEF Supply Division, MSF Logistique, CHAI ARV Access Program, PEPFAR implementers and President's Malaria Initiative commodity pipelines. Donor-specific serialisation, track-and-trace and visibility reporting are built into the dispatch pack as standard.
AMA, EAC, WAHO harmonisation-ready filings
Single dossier base re-used across EAC joint assessment, ECOWAS WAHO ARV and ACT fast-tracks, and future AMA continental assessment. Module 3 stays stable, country Module 1 adapts, artwork is versioned per market. A multi-country filing costs roughly the same as two single-country filings done blind.
Mumbai to Lagos, Mombasa and Durban.
Air is the fast lane. BOM-LOS, BOM-NBO, BOM-JNB, BOM-ADD and BOM-ACC run on an eight-to-sixteen-hour block depending on hub transit. Ethiopian Airlines is the workhorse into Addis and onward across East Africa. Kenya Airways connects Mombasa and Nairobi. Emirates SkyCargo and Qatar Airways run twice-daily widebody capacity via DXB and DOH into Lagos, Johannesburg, Nairobi and Accra. Turkish Cargo adds a third corridor via IST; Saudia Cargo backs up JED routings. Door-to-door for ambient pharmaceutical cargo runs four to seven working days on the East African corridor and five to nine working days on the West African corridor.
Sea is the volume channel. JNPT/Nhava Sheva to Apapa and Tin Can Island runs 21 to 26 days, Mombasa 14 to 18 days, Dar es Salaam 16 to 20 days, Durban 18 to 22 days, Tema 25 to 30 days and Abidjan 28 to 32 days. Maersk, CMA CGM and MSC run the core rotations; less-than-container-load consolidation is available for orders under 12 CBM. Bonded-warehouse options sit behind Mombasa for onward Kampala and Kigali distribution, and behind Durban for the SADC overland route into Zambia, Zimbabwe and Mozambique.
Cold-chain to warm-climate destinations is where most Indian exporters fail. Envirotainer RAP e2 active containers handle the 2-8°C corridor on larger tranches; RKN e1 handles smaller pharma-only shipments; va-Q-tec passive units carry 15-25°C controlled ambient where active power is not practical. Real-time loggers (Berlinger Q-tag CLm doc and ELPRO LIBERO) run on every cold-chain pallet, with a Bluetooth near-field unit for destination handoff. Tarmac dwell at Lagos, Nairobi and Addis routinely reaches 35-45°C; our excursion protocol triggers inside a 30-minute breach of the validated corridor.
Payment and insurance are sized to the buyer. Sovereign and central-stores buyers typically settle on donor-milestone releases or LC at sight through a first-tier African trade bank, with Afreximbank and the African Trade Insurance Agency layering credit-insurance cover where workable. Private hospital groups use TT 30% advance against 70% scanned BL, migrating to open account at 30 to 90 days once the relationship proves out. Cargo runs on Institute Cargo Clauses A, door-to-door.
What we ship most into Africa.
HIV, TB, malaria and reproductive health dominate programmatic volume. Our largest African dispatches sit in first-line antiretrovirals (TLD, tenofovir-lamivudine-dolutegravir, dolutegravir 50 mg, tenofovir-lamivudine, paediatric dispersible formulations), artemisinin-based combination therapies (artemether-lumefantrine, artesunate-amodiaquine, injectable artesunate for severe malaria), and anti-TB fixed-dose combinations across Category I, II and III regimens. Reproductive-health essentials move in consistent tender quantities: misoprostol, oxytocin, magnesium sulfate and methyldopa for pre-eclampsia. Demand flows primarily through Global Fund PPM awards, PEPFAR country programmes, UNICEF Supply Division paediatric ARV consolidations and President's Malaria Initiative pipelines.
Anti-infectives and maternal-health lines cover the broader hospital formulary. Ceftriaxone injection, amoxicillin-clavulanate, doxycycline, metronidazole, azithromycin and meropenem move through central stores and private hospital chains in both tender and direct-order formats. Oncology supportive care and cytotoxics route through private-sector groups such as Aga Khan University Hospital, Nairobi Hospital, Netcare, Lifehealthcare, Reddington Hospital, Mediclinic Southern Africa and regional oncology centres. Paclitaxel, gemcitabine, imatinib, 5-FU and oxaliplatin are the recurring lines; public-sector oncology procurement remains patchy and we do not overstate that channel.
Cardiometabolic and NCD volumes are the fastest-growing slice of the formulary in African tertiary hospitals. Hypertension and type-2 diabetes prevalence is rising across Lagos, Nairobi, Accra, Johannesburg and Addis, and hospital formularies pull steady tender volumes on metformin, glimepiride, amlodipine, telmisartan, losartan, atorvastatin and rosuvastatin. SGLT2 inhibitors and newer ARBs are emerging as tender-eligible lines in South Africa and Egypt. CNS, ophthalmology and critical-care injectables complete the hospital spine. Every line ships with country-specific artwork, CoA per batch and a current GMP certificate.
A Global Fund-funded implementing partner operating across three East African countries consolidated first-line antiretroviral supply under M Care from mid-2024. The scope covered TLD for adult cohorts and paediatric ARV dispersibles against a rolling twelve-month forecast, routed through Mombasa sea freight for the ambient lines and BOM-NBO air for cold-chain biologicals. Across the first 18 months of the arrangement, the programme recorded zero stock-outs at the facility level, a cold-chain excursion rate under 0.5% across 63 consignments, and an average dispatch-to-destination-arrival window of nine days on the air corridor and 19 days on the sea corridor. Temperature loggers were pulled and archived against every consignment; deviation reports were filed inside 24 hours on the two minor excursions that occurred, neither of which breached the stability corridor. The partner has since extended the framework into a second three-year cycle covering two additional therapeutic areas.
Why Indian pharma, why M Care, and what you actually get.
India manufactures roughly 20% of the world's generic finished dosage forms by volume and is the single largest source of antiretrovirals into sub-Saharan Africa through Global Fund and PEPFAR pooled procurement. The structural reasons are clear: WHO-GMP capacity at scale across more than 80 M Care partner sites, a deep API base that keeps finished-product cost 30-50% below European comparators for off-patent molecules, ICH-aligned stability programmes running at Zone IVb (30°C/75%RH) to match African climate conditions, and English-language documentation that slots into NAFDAC, PPB, FDA Ghana, SAHPRA and EFDA dossiers without translation friction. Arabic adaptations for EDA are handled in-house.
The harder question is which Indian supplier. The African market has seen its share of one-container importers who disappear after the first pharmacovigilance query, manufacturers that under-quote and then default on the LC, and consultants who file CPPs authenticated incorrectly and leave the importer with an 18-month stall. M Care sits on the other side of that line. Our Mumbai head office is the regulatory engine room: dossier authoring, CMC review, stability coordination, pharmacovigilance intake and QP release all happen there. Our London desk handles the European-origin audit trail for donor programmes wanting a UK-visibility layer.
Three specifics distinguish the working relationship. First, a single named account manager for your African portfolio, not a rotating pool, with one mobile number and one email from RFQ through re-order. Second, a WHO-PQ and Global Fund track record that means your tender submission is scored on a portfolio the awarding authority has seen perform before, not on a paper claim. Third, multi-country dossier re-use: the same Module 3 anchors NAFDAC, PPB, FDA Ghana, SAHPRA, EFDA, TMDA, NDA and EDA filings, so a four-country footprint costs meaningfully less than four blind single-country filings.
What you will not get: padded lead times, price ratchets on repeat orders, or the documentation gaps that show up three weeks before a KEMSA or NMS tender submission deadline. What you will get: WHO-GMP-sourced product with audit-ready paperwork, a Mumbai engine room that treats a Kampala hospital purchase order with the same seriousness as a London teaching-hospital contract, and honest visibility on what the dossier, the lane and the logger tell you at every step.
Africa pharmaceutical import: common questions.
Which African regulators does M Care routinely file with?
Eight: NAFDAC in Nigeria, PPB in Kenya, FDA Ghana, SAHPRA in South Africa, EFDA in Ethiopia, TMDA in Tanzania, NDA in Uganda and EDA in Egypt. Every dossier is built in ICH CTD or eCTD format with country-specific Module 1 adaptations. Where a molecule qualifies we also file through WHO prequalification, EAC joint assessment and ECOWAS WAHO fast-tracks. CPPs and legalisation chains are managed centrally by the Mumbai team.
Is WHO prequalification required for African tender supply?
For programmatic buys on antiretrovirals, ACTs, anti-TB fixed-dose combinations and reproductive-health commodities, WHO-PQ status is usually either a precondition or a material scoring advantage. Global Fund PPM buys and UNICEF Supply Division paediatric ARV consolidations are WHO-PQ-gated by policy. For non-programmatic hospital formulary lines, country national registration is sufficient. M Care carries WHO-PQ status on the relevant ARV, ACT, TB and reproductive-health lines.
Does M Care supply the Global Fund, PEPFAR and UNICEF?
Yes. We dispatch to Global Fund PPM awards and the Wambo.org marketplace, to PEPFAR programmes via SCMS/Chemonics and direct country implementers, to UNICEF Supply Division in Copenhagen for paediatric ARV and reproductive-health consolidations, and to MSF Logistique for emergency and field-programme supply. The CHAI ARV Access Program and President's Malaria Initiative are regular counterparties. Donor-specific serialisation and visibility reporting are standard on the dispatch pack.
What is the AMA and how does it affect multi-country registration?
AMA is the African Medicines Agency, the continental regulator envisaged under the African Union treaty that entered into force on 5 November 2019. The secretariat is being stood up in Kigali and operational rollout is phased through the late 2020s. AMA does not yet replace national registration with NAFDAC, PPB, SAHPRA or EDA. It will progressively provide a continental pathway for priority medicines. We author dossiers today in a structure that will re-use into AMA assessment.
How does cold-chain work to warm-climate destinations?
Validated active containers on the 2-8°C corridor (Envirotainer RAP e2 or RKN e1), va-Q-tec passive units on the 15-25°C corridor, continuous temperature logging through Berlinger Q-tag and ELPRO LIBERO loggers, cool-dolly handover at transit and destination, and a generator-backed warehouse with 72-hour autonomy. Tarmac dwell at Lagos, Nairobi, Addis and Accra runs 35-45°C in peak season. Excursion protocol triggers at a 30-minute breach.
Can M Care bid on central-medical-stores tenders?
Yes. We file into KEMSA, NMS Uganda, JMS Uganda, MSD Tanzania, CMS Ghana, EPSS Ethiopia and the relevant Francophone regional stores. Tender cycles run two to three years with annual refreshes. We pre-position the technical pack (CTD extract, stability under Zone IVb, GMP certificate, CPP, WHO-PQ status where applicable, artwork and pro-forma) and coordinate the local-agent filings each store requires.
How long does NAFDAC product registration take?
For a complete Category-A dossier with a clean WHO-GMP certificate, CPP, full stability under ICH Zone IVb and bioequivalence documentation, NAFDAC moves a generic from first submission to marketing authorisation inside six to twelve months. Incomplete files stall; the first deficiency letter arrives at month three to four, and we answer inside two weeks. NAFDAC also applies the MAS scratch-panel requirement to antimalarials, antibiotics and oxytocics.
Do you supply Francophone and Anglophone African markets?
Yes. Anglophone West Africa runs through NAFDAC and FDA Ghana under ECOWAS WAHO harmonisation. Anglophone East Africa runs through PPB, NDA, TMDA and the EAC joint-assessment programme. Southern Africa runs through SAHPRA. Francophone West and Central Africa sits under UEMOA and OCEAC harmonisation with WAHO ARV and ACT fast-tracks; dossiers are authored in French with the same Module 3 substrate. North Africa runs through EDA with Arabic artwork mandatory.
Why buyers choose M Care for the India → Africa corridor.
Multi-regulator fluency
Dossiers built to the exact format NAFDAC, PPB, FDA Ghana, SAHPRA, EFDA, TMDA, NDA and EDA reviewers read, not a generic CTD dump. We know which modules each authority scrutinises first, which stability windows trigger queries, and which legalisation and apostille chain each submission needs to clear on the first pass. WHO-PQ and EAC joint-assessment pathways are invoked where the molecule qualifies.
Logistics for warm-climate freight
Validated Envirotainer and va-Q-tec cold-chain kit across BOM-LOS, BOM-NBO, BOM-JNB, BOM-ADD and BOM-ACC, continuous temperature logging, cool-dolly handover at transit hubs, and generator-backed destination warehousing with 72-hour autonomy. Tarmac dwell at 35-45°C is a design constraint, not a surprise. Excursion protocol triggers inside 30 minutes.
Commercial discipline, one point of contact
USD, EUR or GBP invoicing with clear FX-clause language, LC at sight and donor-milestone settlement options for sovereign and NGO buyers, open-account progression as the relationship proves out, 18 therapeutic areas on one purchase order, and one named account manager from enquiry through clearance at destination. No rotating pool.
Top categories we ship to Africa
Anti-infectives
ARVs, ACTs, anti-TB FDCs, cephalosporins, carbapenems, antifungals, antivirals. WHO-PQ portfolio anchors the Global Fund, PEPFAR and UNICEF supply lines; broader hospital formulary covers ceftriaxone, meropenem and azithromycin.
Oncology
Cytotoxics and supportive care for private-sector hospital chains: paclitaxel, gemcitabine, imatinib, 5-FU, oxaliplatin. Aga Khan, Nairobi Hospital, Netcare, Lifehealthcare and Reddington are representative buyers.
Cardiovascular
Antihypertensives, statins, antiarrhythmics and heart-failure lines: amlodipine, telmisartan, losartan, atorvastatin, rosuvastatin. Rising tender volumes across South Africa, Kenya, Nigeria and Egypt.
Diabetes & endocrine
Metformin, glimepiride, newer SGLT2 inhibitors in South Africa and Egypt, thyroid and hormonal therapy, human and analogue insulins in validated cold-chain across 470+ lines.
CNS & neurology
Antiepileptics, antipsychotics, antidepressants, anxiolytics and neuroprotective lines supporting teaching hospitals and psychiatric services across the continent.
General & OTC
Analgesics, vitamins, wound-care, nutritionals and maternal-health commodities — 1,283 SKUs, the broadest slice of the catalogue, with both tender and private-retail channels served.
Routes that sit behind this region.
NGO pharmaceutical procurement
Manufacturer-side supply into Global Fund PPM, UNICEF Supply Division, MSF Logistique, CHAI ARV Access, PEPFAR implementers and President's Malaria Initiative pipelines. Donor-specific serialisation, visibility reporting and milestone-release settlement built in as standard.
WHO-GMP compliance
WHO-GMP-sourced finished dosage forms across 80+ partner sites, with CDSCO export licensure, CPPs, apostille and legalisation handled centrally. WHO TRS 986 Annex 2 and WHO-PQ inspection-ready documentation, audit trail-complete on every dispatch.
Cold-chain validation
Envirotainer RAP e2, RKN e1 and va-Q-tec passive systems qualified for 2-8°C and 15-25°C corridors. Real-time Berlinger and ELPRO logging, excursion protocol at 30-minute breach, generator-backed destination warehousing with 72-hour autonomy.
Molecule, volume, target market. One working day to a quote.
Your enquiry lands with the named account manager for the African corridor. Regulatory, logistics and commercial answers in the turnaround your tender file needs.
Start an Africa enquiry → Back to all markets